UK markets closed

Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.3000+0.0100 (+0.30%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5321.75M
Enterprise value 3344.55M
Trailing P/E N/A
Forward P/E 1-4.93
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)46.54
Price/book (mrq)N/A
Enterprise value/revenue 349.83
Enterprise value/EBITDA 7-6.23

Trading information

Stock price history

Beta (5Y monthly) 2.93
52-week change 3214.29%
S&P500 52-week change 349.51%
52-week high 39.0200
52-week low 31.0100
50-day moving average 33.5653
200-day moving average 33.6332

Share statistics

Avg vol (3-month) 32.5M
Avg vol (10-day) 31.05M
Shares outstanding 595.58M
Implied shares outstanding 696.75M
Float 69.81M
% held by insiders 118.71%
% held by institutions 125.42%
Shares short (14 Mar 2021) 43.9M
Short ratio (14 Mar 2021) 41.63
Short % of float (14 Mar 2021) 45.00%
Short % of shares outstanding (14 Mar 2021) 44.03%
Shares short (prior month 11 Feb 2021) 42.55M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:5
Last split date 303 Nov 2010

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Dec 2020


Profit margin 0.00%
Operating margin (ttm)-828.30%

Management effectiveness

Return on assets (ttm)-29.51%
Return on equity (ttm)-72.97%

Income statement

Revenue (ttm)6.91M
Revenue per share (ttm)0.09
Quarterly revenue growth (yoy)47.50%
Gross profit (ttm)-40.57M
EBITDA -55.29M
Net income avi to common (ttm)-75.87M
Diluted EPS (ttm)-1.0000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)123.27M
Total cash per share (mrq)1.29
Total debt (mrq)2.98M
Total debt/equity (mrq)2.92
Current ratio (mrq)13.39
Book value per share (mrq)-0.53

Cash flow statement

Operating cash flow (ttm)-51.44M
Levered free cash flow (ttm)-30.17M